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Abstract: 
Orthogonally protected 1,2-diaminopropanoic acids (DAPs) have been synthesised in 
good yields by the ring-opening of 3-unsubstituted N-activated aziridine 2-
carboxylates with para-methoxybenzylamine. The choice of both the N-activating 
group and ester alkyl group had a significant influence on the ratio of attack at the α 
or β positions of the aziridine. However, the regiochemical outcome is not 
predictable. 
 
Keywords: 
1,2-Diaminopropanoic acids (DAPs); Aziridine 2-carboxylates; Ring-opening; 
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Interest in α,β-diaminopropanoic acids [1,2-diaminopropanoic acids (DAPs)] has 
expanded over the years, as evidenced by the increase in publications in the area. A 
recent review,1 and its update,2 have highlighted methodologies for their synthesis, as 
well as their possible applications and biological activities. Natural biologically active 
molecules, which contain the α,β-diaminopropanoic acid motif, are known and they 
are stereochemically pure as single enantiomers or diastereoisomers. Therefore 
methods from the stereoselective synthesis of α,β-diaminopropanoic acids are very 
important. In this context, the use of α-amino acid derivatives from the chiral pool, 
where one or more stereocentres are already present, as precursors for α,β-
diaminopropanoic acids, is a key method that has been employed. One of the main 
routes employed for the synthesis of DAPs is the ring-opening of N-activated 
aziridine 2-carboxylate esters with primary amines. Although there is a large body of 
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literature on the ring-opening of aziridines in general,3 as well as 2-acyl aziridines4 
and N-activated aziridines,5 the number of reports on the ring-opening of N-activated 
aziridine 2-carboxylate esters is fewer. In all such reactions the nucleophile can attack 
at either the α- or β-position of the aziridine ring to give regioisomeric products 
(Figure 1).  
 
In a recent review,3a De Kimpe and Ha stated that “the regioselectivity in the ring-
opening reactions of 2-substituted activated aziridines has been shown to be quite 
straightforward, mostly involving the nucleophilic attack at the less hindered carbon 
atom, with some exceptional cases comprising the nucleophilic attack at the benzylic 
position”. An examination of the regioselectivity of these reactions shows that the 
outcome is not always that predictable,6 particularly when the nucleophile is a 
primary amine, and the 2-substituent is also electron-withdrawing (e.g. an ester 
group).  For example, Rich found that reaction of N-tosyl aziridine 2-carboxylic acid 
with methylamine gave a 1:1 ratio of products resulting from α- and β-attack.7 
However, when the steric hindrance at the 2-position was increased, by using the 2-
tert-butyl ester derivative, the α:β ratio was 1:6.3. The van Boom group found a 3.5:1 
ratio, in favour of attack at the less hindered β-position, for the reaction of 
benzylamine with N-ortho-nitrobenzenesulfonyl (o-Ns) azridine 2-t-butyl ester, which 
increased to a 15-17:1 ratio when the primary amine was an α-amino acid ester.8 
When the steric hindrance was increased significantly, by linking the ester group at 
the aziridine 2-position to a solid support, Olsen found that this led to exclusive attack 
at the less hindered β-position, with no evidence for any α-attack.9 The Franzyk group 
reported a 9:1 ratio, in favour of β-attack, when the ester group of an α-amino ester 
was linked to a solid support, and it was reacted with N-pNs aziridine methyl 2-
carboxylate.5h 
 
As part of an ongoing programme of research towards the synthesis of peptides 
incorporating unusual amino acid residues, we are interested in the synthesis of β-
monoalkyl substituted 1,2-diaminopropanoic acids (DAPs). In particular, the use of 
orthogonally protected DAPs would allow their incorporation into peptide structures 
and then their subsequent derivatisation. We previously reported the synthesis, and 
subsequent use, of such orthogonally protected DAPs for the preparation of 
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orthogonally protected azalanthionines (lanazanines), which are nitrogen-linked 
analogues of the more common amino acid lanthionine (Figure 2).10  
 
The required DAPs were prepared by the ring-opening of 3-unsubstituted N-activated 
aziridine 2-carboxylate esters with benzylamines, or by the Mitsunobu reaction of 
serine derivatives.11 During the aziridine ring-opening reactions it was found that 
there were issues with the regioselectivity of the reactions, depending on the choice of 
N-protecting group and ester group at the aziridine 2-position. Since the initial results 
showed that the regiochemical outcome was not straightforward, an extended study 
was undertaken to determine whether the regioselectivity was in any way predictable. 
The required N-activated aziridine 2-carboxylates were prepared as shown in Scheme 
1.10,12  
 
In each case the protecting groups chosen were those that have been used previously 
in solid-phase peptide syntheses, particularly in the preparation of lanthionine 
containing peptides and their analogues.12 Thus the N-protecting groups used were Ts, 
para-nitrobenzenesulfonyl (p-Ns) and para-nitrobenzyloxycarbony (p-Nz), while the 
methyl and allyl esters were chosen for the aziridine 2-position. Preparation of a DAP 
with the β-amino group also being protected was achieved by ring-opening of 
aziridine 2a with para-methoxybenzylamine (PMB-NH2) following the method of 
Kim.13 This involved heating the reaction to 80 oC in acetonitrile for 24 hours with 
two molar equivalents of PMB-NH2, which gave the two regioisomeric products from 
nucleophilic attack at either the α- or β-positions of the aziridine. The PMB group 
was chosen because it can be easily removed in solid-phase synthesis. The yield of the 
product (Table 1) from attack at the less hindered β-position was 32%, while attack at 
the α-position gave a 41% yield (entry 1).  
 
Conducting the reaction at room temperature for 24 hours gave a reversal in the 
observed selectivity, with the β-attack giving a yield of 70% and α-attack of 23% 
(entry 2). The selectivity observed at higher temperatures was not unexpected, but the 
23% yield of the compound isolated from attack at the hindered α-position, at room 
temperature, was somewhat of a surprise. Since the conditions required to remove the 
tosyl group are very harsh for solid-phase peptide synthesis the alternative N-
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activating, peptide-friendly, p-Ns and p-Nz groups were chosen, for comparison with 
the N-tosyl aziridine 2a. (Note: the N-Fmoc protected aziridine was not chosen 
because it was felt that the secondary amino DAP product might lead to a loss of the 
Fmoc group). As can be seen, from Table 1, the p-Ns protected aziridine methyl ester 
3a (entry 3) gave a similar result to aziridine 2a (63% β and 21% α). However, when 
the p-Nz group was used there was no product obtained from attack at the hindered α-
position, with the DAP product 6c, from attack at the β-position, being the sole 
product isolated in a yield of 56% (entry 4). This result is comparable to the outcome 
of Harada’s study of the reaction of a 2-carboxamido N-Cbz aziridine with m-
methylbenzylamine in toluene at 80 oC, where the product from attack at the β-
position was the sole product isolated, in a 79% yield.14 It therefore appears that 
incorporation of a sulfonamide group on the aziridine nitrogen leads to an increase in 
the amount of nucleophilic attack at the hindered α-position. It was thought that 
perhaps the increased electron-withdrawing properties of the sulfonamide group were 
responsible for this.  
 
Therefore, in order to extend this study, it was thought that changing the ester methyl 
group, again to the more peptide-friendly allyl ester group, would be advantageous. 
However, this small change led to some surprising results (Table 1). To keep the 
results comparable PMB-NH2 was again used as the nucleophile. In this case 
aziridines 2b and 3b did not give any reaction products (entries 5 and 6), at either 
room temperature or at 80 oC in acetonitrile, while the p-Nz aziridine 4b again gave 
only β-attack, giving DAP 6d, in an isolated yield of 66% (entry 7). The N-alloc 
protected aziridine allyl ester 5b also did not give any reaction at either room 
temperature or 80 oC (entry 8), which was surprising when compared to Harada’s 
study with a Cbz-protected aziridine (vide supra). 
 
It was clear that the observed regioselectivity of ring-opening was not predictable, 
with small changes in the choice of activating groups leading to quite different 
outcomes. Since the primary amine employed in these studies was kept constant we 
next examined the aziridine partner, in order to try to understand the observed 
regioselectivity. Perhaps an analysis of the 1H NMR chemicals shifts of the α- and β-
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protons of the aziridine rings, along with their corresponding carbon chemical shifts 
in 13C NMR spectra, would help the understanding of the observed results (Table 2).  
 
However, it can be seen that there is very little difference between the analogous 1H 
and 13C NMR spectral chemical shifts of the aziridines 2-5. It is therefore difficult to 
make a definitive prediction of the regioselectivity for a particular ring-opening 
reaction of 3-unsubstituted N-activated aziridine 2-carboxylate esters with a primary 
amine. 
 
In conclusion, we have shown that the ring-opening of N-activated aziridine 2-
carboxylate esters with p-methoxybenzylamine is far from predictable. We are 
currently undertaking in-depth computational studies on these reactions, including an 
examination of possible transition states and their energies, in order to try to 
understand the experimental results observed. The chemistry is also being extended to 
the synthesis of the corresponding orthogonally protected β-methyl DAPs, by ring-
opening of 3-methyl N-activated aziridine 2-carboxylate esters, en route to the aza 
analogues of the β-methyllanthionines found in the ring structures of many important 
lantibiotics.15 The results of all of these studies will be reported in due course. 
 
A typical procedure is exemplified by the synthesis of 6a and 7a. To a solution of the 
relevant aziridine (2 mmol) in CH3CN (5 ml) was added p-methoxybenzylamine (0.52 
ml, 4 mmol) and the solution was stirred for 24 h at room temperature. The solvent 
was removed in vacuo, and then the residue was re-dissolved in EtOAc (20 ml), 
washed with brine (2 x 20 ml), dried over anhydrous MgSO4 and concentrated in 
vacuo. The crude product was purified by flash column chromatography on silica gel 
in petroleum ether: EtOAc (2:1). 
 
(L)-Methyl 3-(4-methoxybenzylamino)-2-(4-methylphenylsulfonamido) propanoate 
(6a). Colourless oil (0.54 g, 70%); Rf: 0.12 petroleum ether: EtOAc (1:1); [α]D20 = 
+13.35 (c 1.0 in CHCl3);  1H NMR (CDCl3, δ ppm) 7.72 (d, 2H, J = 8.2 Hz), 7.28 (d, 
2H, J = 8.8 Hz), 7.16 (d, 2H, J = 8.8 Hz), 6.85 (d, 2H, J = 8.8 Hz), 4.03 (t, 1H, J = 4.8 
Hz),  3.79 (s, 3H), 3.65 (d, 1H, J = 12.9 Hz), 3.61 (d, 1H, J = 12.9 Hz), 3.52 (s, 3H), 
2.88 (d, 2H, J = 5.2 Hz), 2.40 (s, 3H); 13C NMR (CDCl3, δ ppm) 171.2, 158.7, 143.7, 
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136.6, 131.3, 129.6, 129.3, 127.2, 113.8, 60.4, 55.3, 52.6, 52.3, 50.0, 21.5; IR (thin 
film, NaCl, cm-1)  3347, 3089, 2981, 1744, 1188, 1150;  MS (ES+) for C19H25N2O5S, 
expected [M+H] 393.1479, observed [M+H] 393.1477. 
 
(D)-Methyl 2-(4-methoxybenzylamino)-3-(4-methoxyphenylsulfonamido) propanoate 
(7a). Colourless oil (0.17 g, 23%); Rf: 0.24 petroleum ether: EtOAc (1:1); [α]D20 = 
+12.41 (c 1.0 in CHCl3);  1H NMR (CDCl3, δ ppm) 7.70 (d, 2H, J = 8.6 Hz), 7.28 (d, 
2H, J = 8.0 Hz), 7.15 (d, 2H, J = 8.6 Hz), 6.85 (d, 2H, J = 8.6 Hz), 5.15 (br s, 1H) 3.80 
(s, 3H), 3.68 (s, 3H), 3.65 (m, 2H), 3.51 (d, 1H, J = 12.9 Hz), 3.30 (m, 1H), 3.26 (dd, 
1H, J = 8.6 Hz and J = 8.6  Hz), 2.95 (dd, 1H,  J = 7.5 Hz and J = 7.4 Hz), 2.41 (s, 
3H), 1.88 (br s, 1H); 13C NMR (CDCl3, δ ppm) 172.9, 158.9, 143.5, 136.6, 131.0, 
129.7, 129.4, 127.0, 113.9, 59.0, 55.3, 52.3, 51.2, 44.2, 21.5; IR (thin film, NaCl, cm-1) 
3359, 3082, 2991, 1743, 1224, 1124. 
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Figure 1: Regiochemistry of nucleophilic ring-opening of N-activated aziridine 2-
carboxylates 
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Figure 2: Synthesis of orthogonally protected azalanthionines (lanazanines)10 
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Scheme 1: Synthesis of N-activated aziridine 2-carboxylate esters10,12 
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Entry Aziridine % β-attacka % α-attacka 
1 
2 
2a (R = Me, EWG = Ts) 
2a (R = Me, EWG = Ts) 
  32 (6a)b 
70 (6a) 
 41 (7a)b  
23 (7a) 
3 3a (R = Me, EWG = p-Ns) 63 (6b) 21 (7b) 
4 4a (R = Me, EWG = p-Nz) 56 (6c) - 
5 2b (R = Allyl, EWG = Ts) 
- - 
6 3b (R = Allyl, EWG = p-Ns) 
- - 
7 4b (R = Allyl, EWG = p-Nz) 66 (6d) - 
8 5b (R = Allyl, EWG = Alloc) 
- - 
a
 Product number is in parantheses; b Reaction conducted at 80 oC. 
Table 1: Regioselectivity of the ring-opening of aziridines with p-
methoxybenzylamine.
 
 
 
 
Aziridine α-H β-H α-C β-C 
2a 3.33 2.76 and 2.59 35.6 31.9 
3a 3.38 2.83 and 2.60 36.1 32.5 
4a 3.09 2.57 and 2.45 35.0 31.4 
2b 3.36 2.76 and 2.58 35.8 32.0 
3b 3.47 2.91 and 2.68 36.3 32.5 
4b 3.22 2.65 and 2.57 34.9 31.4 
5b 3.13 2.61 and 2.50 31.3 29.7 
 
Table 2: 1H (300 MHz) and 13C (75 MHz) NMR chemical shifts (in ppm) of the α- 
and β-protons and carbons of aziridines 2-5, run in CDCl3 
 
 
